This milestone marks a significant step forward in Rakovina’s mission to accelerate drug discovery using advanced AI-driven platforms. In September 2024, Rakovina announced its partnership with ...

Rakovina Therapeutics Inc. has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in ...

Aprea’s ATR inhibitor program is protected by a strong patent estate, including four granted U.S. patents, one pending U.S. application, and one pending provisional application. There are 19 ...

Repare Therapeutics is set to cut approximately 75% of its workforce as part of a restructuring plan aimed at extending its cash reserves into mid-2027. The oncology biotech, based in Montreal and ...

Chief among them was a combination of the biotech’s PKMYT1 inhibitor lunresertib and ATR inhibitor camonsertib, dubbed Lunre+Camo. When asked by Fierce Biotech about how staff would be impacted ...

With a robust and expanding patent estate, Aprea’s assets include four U.S. patents, one pending U.S. application, and one provisional application for its ATR inhibitor program. Globally ...

Following a rigorous AI-driven selection process, the company shortlisted the most promising ATR inhibitor candidates for synthesis. The first batch of these compounds will now move into preclinical ...

The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.